Latest PCSK9 Stories
PCSK9 inhibitors could cost the health care system as much as $150 billion annually WOONSOCKET, R.I., Feb.
Primary efficacy endpoints met in two trials of alirocumab administered every four weeks TARRYTOWN, N.Y. and PARIS, Jan. 9, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent THOUSAND OAKS, Calif., Nov.
Thirteen Presentations Include New Analyses of PCSK9 Inhibitor at Upcoming American Heart Association Scientific Sessions THOUSAND OAKS, Calif., Nov.
THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
A team of researchers at the University of Ottawa Heart Institute, led by Dr. Alexandre Stewart, have uncovered an intriguing link between heart attacks and a protein that is of great interest to drug companies for its impact on cholesterol.
Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug.
Companies to Host Investor Conference Call on Alirocumab on March 31 at 9 AM EDT PARIS and TARRYTOWN, N.Y., March 27, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY)